论文部分内容阅读
将2，2，15细胞接种裸鼠，制得抗乙型肝炎病毒（HBV）动物模型。用125I标记乙型肝炎导向干扰素（T－IFN），观察放射标记物（125I－T－IFN）在荷瘤鼠体内的分布情况，以评价T－IFN在体内的抗HBV导向治疗作用。结果显示，125I－T－IFN在各组织浓度顺序依次为：瘤＞心＞肝＞脾＞肾，且瘤组织与其它各组织比较，有明显差异（P＜0．01）。结果表明，在HBV动物模型体内，T－IFN相对浓集于可分泌HBsAg的瘤区。实验结果显示了T-IFN导向治疗HBV感染的可行性。
The nude mice were inoculated with 2,2,15 cells to prepare anti-hepatitis B virus (HBV) animal model. Hepatitis B-interferon (T-IFN) was labeled with 125I, and the distribution of 125I-T-IFN in tumor-bearing mice was observed to evaluate the anti-HBV therapeutic effect of T-IFN in vivo. The results showed that the concentration of 125I-T-IFN in each tissue was in the order of tumor> heart> liver> spleen> kidney, and the tumor tissue was significantly different from other tissues (P <0.01). The results showed that in the body of HBV animal model, T-IFN was relatively concentrated in the tumor area secreting HBsAg. The experimental results show the feasibility of T-IFN directed treatment of HBV infection.